Key points The incretin hormone glucagon-like peptide 1 (GLP1) promotes satiety and potentiates insulin release and suppression of glucagon release in response to the ingestion of nutrients
The possible effect of the long-term use of glucagon-like peptide-1 receptor agonists (GLP-1RA) on Hba1c and lipid profile in type 2 diabetes mellitus: a retrospective study in KAUH, Jeddah, Saudi Arabia
There is no universal best for every individual but from a receptor-complexity perspective, triple agonists currently represent the most advanced metabolic approach under investigation
Semaglutide enhances insulin sensitivity, slows stomach emptying, and leads to better nutrient absorption and stable blood sugar
Weight loss and metabolic risk in obese children
Researchers eventually renamed it glucose-dependent insulinotropic polypeptide , which more accurately reflects its role in regulating blood sugar after meals